# STX-003

Source: https://onco.cc/drugs/stx-003/  
OnCo record `stx-003` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

STX-003 is an experimental self-replicating mRNA circuit in lipid nanoparticle from Strand Therapeutics, in phase 1 trials for non-small cell lung cancer and advanced solid tumours.

## Summary

STX-003 is a self-replicating mRNA circuit in lipid nanoparticle (intravenous) from Strand Therapeutics. A systemically delivered self-replicating mRNA encoding IL-12 with microRNA target sites, so that it is expressed in tumour cells and switched off elsewhere. Its furthest stage is phase 1, for non-small cell lung cancer and advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 recruiting, started 2026-06-30 (registry), alone and with pembrolizumab. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: STX-003
- Modality: Self-replicating mRNA circuit in lipid nanoparticle (intravenous)
- Mechanism: A systemically delivered self-replicating mRNA encoding IL-12 with microRNA target sites, so that it is expressed in tumour cells and switched off elsewhere.

## Sources

- Strand Therapeutics: strandtx.com: https://www.strandtx.com/pipeline
- Strand Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07751042
- ClinicalTrials.gov: trials of STX-003: https://clinicaltrials.gov/search?intr=STX-003

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Strand Therapeutics](https://onco.cc/companies/strand-therapeutics/)
- trials: [Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab](https://onco.cc/trials/nct07751042/)

---
JSON: https://onco.cc/api/v1/entities/stx-003.json